Opus Genetics (IRD) Q2 2024 earnings summary

Executive summary

• Net loss for Q2 2024 was $7.8 million, up from $5.0 million in Q2 2023, with a six-month net loss of $14.9 million compared to $10.8 million year-over-year.

• License and collaboration revenue for Q2 2024 was $1.1 million, down from $3.7 million in Q2 2023, primarily from the Viatris License Agreement.

• RYZUMVI, the FDA-approved product, was launched commercially in April 2024, generating initial royalties of $19,000.

• VEGA-3 and LYNX-2 Phase 3 studies of phentolamine ophthalmic solution are actively enrolling, with topline data expected in 2025.

• Preparations for Phase 2/3 trial of APX3330 in diabetic retinopathy are ongoing, with continued FDA engagement.

Financial highlights

• Cash and cash equivalents as of June 30, 2024, were $41.4 million, down from $50.5 million at year-end 2023.

• Total operating expenses for Q2 2024 were $9.4 million, up from $9.1 million in Q2 2023.

• General and administrative expenses decreased to $3.4 million from $4.3 million year-over-year, while research and development expenses increased to $6.1 million from $4.7 million.

• Stock-based compensation for Q2 2024 was $0.5 million (G&A) and $0.3 million (R&D); $1.8 million for the six months ended June 30, 2024.

• Weighted average shares outstanding for Q2 2024 were 25.8 million.

Outlook and guidance

• Cash on hand is expected to fund operations for at least twelve months beyond the filing date and into mid-2025.

• Topline data from VEGA-3 and LYNX-2 Phase 3 trials expected in 2025; LYNX-3 study planned for 2024.

• Revenue is expected to remain limited until further regulatory approvals or significant RYZUMVI sales.